TSO3 Inc.

Stryker, through a subsidiary, will acquire TSO3, a medical device sterilization technology company, for $0.43 per share in cash. The total enterprise value is approximately $68.4 million (US$51.7 million).

TSO3 Inc. was awarded a sole-source contract by CHU de Québec - Université Laval for one STERIZONE VP4 Sterilizer, with an option for up to two additional sterilizers, under a Quebec tender.

TSO3 and Getinge Infection Control AB mutually decided not to renew distribution agreements; TSO3 will purchase approximately 230 STERIZONE VP4 Sterilizers from Getinge's inventory for $33,000 each.

TSO3 Inc. has closed a US$20 million debt financing with a fund advised by Courage Capital Management to fund commercialization of its STERIZONE VP4 Sterilizer.